Report Overview
The Asia-Pacific nuclear medicine market is projected to grow at a CAGR of 6.56% between 2025 to 2030.
As it is a superior technique over traditional imaging methods, it is being widely employed by healthcare facilities. The Asia-Pacific countries are improving their health sector by introducing advanced methods of treatment. This is another market driver.
Thirdly, the growing incidences of cancer, cardiovascular disease, and thyroids in these countries are demanding better diagnostic techniques. The nuclear medicine market can avail these opportunities in the region to expand their market.
Growth Factors.
Increase incidence of diseases.
According to WHO, there were nearly 10 million deaths due to cancer worldwide. The number of deaths in the Asia-Pacific region is also increasing. Likewise, cardiovascular diseases are also increasing among the population. An estimated 17.9 million people died from cardio-related diseases in 2019, representing 32% of all global deaths. The numbers of deaths are more in low developing countries because of poor diagnostic facilities. This region accounts for high rates of poverty and skewed income distribution exposing the population to more diseases. Nuclear medicines can bring about changes to these affairs and eventually develop a market in these countries.
R&D and Innovations.
As the numbers of research facilities grow in Asia-Pacific countries especially China and Japan, medical advancements have been flourishing. Research and studies are conducted to enhance radiotherapy for various diseases such as thyroid-related diseases, respiratory diseases, bone diseases, and neurological diseases. In addition, radiopharmaceuticals are being extensively used in molecular imaging, a technique involving molecules as biomarkers for specific molecular processes that determine the onset and/or progress of a disease. This is expected to drive the market for nuclear medicine during the forecast period.
Restraint.
Nuclear medicine is an efficient medical technique. But the growing inequality in the region is a strong restricting market factor. The lower strata of the society are unable to afford the services. The government-sponsored health sector also fails to provide these services in the truest sense. These causes have debarred the market from fully expanding in the region. Then again, government initiatives and funding for the development of new techniques are anticipated to drive the nuclear medicine market in the long run.
Competitive Insights.
The market leaders for the Asia-Pacific Nuclear Medicine are Bracco Diagnostic Inc.[1], Koninklijke Philips N.V, Curium, Lantheus Medical Imaging, Inc., Mitsubishi, Sterigenics International., GE Healthcare, Fujifilm Holdings Corporation, Cardinal Health, and SC Health Corp. The key players in the market implement growth strategies such as product launches, mergers, and acquisitions, etc. to gain a competitive advantage over their competitors. For instance,
Asia Pacific Nuclear Medicine Market Scope
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | 6.56% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Technology, Application, End-User, Country |
| Companies |
|
Market Segmentation
By Technology
- PET
- SPECT
By Application
- Central Nervous System
- Endocrine
- Skeletal
- Gastrointestinal
- Genitourinary
- Pulmonary
By End-User
- Hospitals
- Diagnostic Centres
- Research Institutions
By Country
- India
- China
- Japan
- Thailand
- Indonesia
- Taiwan
- Others
Table of Contents
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis
5. ASIA PACIFIC NUCLEAR MEDICINE MARKET BY TECHNOLOGY
5.1. PET
5.2. SPECT
6. ASIA PACIFIC NUCLEAR MEDICINE MARKET BY APPLICATION
6.1. Central Nervous System
6.2. Endocrine
6.3. Skeletal
6.4. Gastrointestinal
6.5. Genitourinary
6.6. Pulmonary
7. ASIA PACIFIC NUCLEAR MEDICINE MARKET BY END-USER
7.1. Hospitals
7.2. Diagnostic Centres
7.3. Research Institutions
8. ASIA PACIFIC NUCLEAR MEDICINE MARKET BY COUNTRY
8.1. India
8.2. China
8.3. Japan
8.4. Thailand
8.5. Indonesia
8.6. Taiwan
8.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
13.1. Major Players and Strategy Analysis
13.2. Emerging Players and Market Lucrative
13.3. Mergers, Acquisition, Agreements, and Collaborations
13.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Bracco Diagnostic Inc.
10.2. Koninklijke Philips N.V
10.3. Curium
10.4. Lantheus Medical Imaging, Inc.
10.5. Mitsubishi
10.6. Sterigenics International
10.7. GE Healthcare
10.8. FUJIFILM Holdings Corporation
10.9. Cardinal Health
10.10. SC Health Corp
Request Customization
Tell us your specific requirements and we will customize this report for you.
Download Free Sample
Get a sample copy of this report with charts, TOC, and methodology.
Speak to Analyst
Ask our analysts any questions you have about this market research report.
Asia Pacific Nuclear Medicine Market Report
Trusted by the world's leading organizations
